Advertisement

Ghrelin Regulation of AMPK in the Hypothalamus and Peripheral Tissues

  • Miski Scerif
  • Blerina Kola
  • Márta KorbonitsEmail author
Chapter
Part of the Contemporary Endocrinology book series (COE, volume 10)

Abstract

Adenosine 5′ monophosphate-activated protein kinase (AMPK) is a regulator of cellular and systemic energy homeostasis. Several appetite-regulating and metabolic hormones are known to influence AMPK. Ghrelin displays central orexigenic as well as direct peripheral metabolic effects and both could be related to its effects on AMPK activity. In the hypothalamus ghrelin stimulates AMPK and this has been associated with its orexigenic effects. Evidence suggests a tight interaction between the central ghrelin and cannabinoid systems, and hypothalamic AMPK appears to be a common mediator of their orexigenic effects. In the liver and adipose tissue, ghrelin inhibits AMPK and this could be the underlying mechanism for its diabetogenic and lipogenic effects. While in cardiac muscle, ghrelin stimulates AMPK which could be linked to its positive inotropic effects. In summary, tissue-specific alterations of AMPK activity play an important role in the diverse effects of ghrelin.

Keywords

Fatty Acid Amide Hydrolase CPT1 Activity Orexigenic Effect Ghrelin Treatment Central Ghrelin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We are very grateful for the Rod Flower Summer Vacation Scholarship (MS), the sponsorship by Goldberg-Schachmann & Freda Becker Trusts (MS) and the Wellcome Trust Research Grant (BK, MK).

References

  1. 1.
    Carling D. AMPK. Curr Biol. 2004;14:R220.PubMedGoogle Scholar
  2. 2.
    Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15–25.PubMedGoogle Scholar
  3. 3.
    Xiao B, Heath R, Saiu P, et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature. 2007;449:496–500.PubMedGoogle Scholar
  4. 4.
    Kola B, Boscaro M, Rutter GA, Grossman AB, Korbonits M. Expanding role of AMPK in endocrinology. Trends Endocrinol Metab. 2006;17:205–15.PubMedGoogle Scholar
  5. 5.
    Hardie DG, Sakamoto K. AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology (Bethesda). 2006;21:48–60.Google Scholar
  6. 6.
    Daval M, Foufelle F, Ferre P. Functions of AMP-activated protein kinase in adipose tissue. J Physiol. 2006;574:55–62.PubMedGoogle Scholar
  7. 7.
    Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol. 2010;44:87–97.PubMedGoogle Scholar
  8. 8.
    Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J. 2007; 403:139–48.PubMedGoogle Scholar
  9. 9.
    Costanzo-Garvey DL, Pfluger PT, Dougherty MK, et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab. 2009;10:366–78.PubMedGoogle Scholar
  10. 10.
    Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 2010;1804:581–91.PubMedGoogle Scholar
  11. 11.
    Bungard D, Fuerth BJ, Zeng PY, et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science. 2010;329:1201–5.PubMedGoogle Scholar
  12. 12.
    Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428:569–74.PubMedGoogle Scholar
  13. 13.
    Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415:339–43.PubMedGoogle Scholar
  14. 14.
    Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes. 2003;52:1355–63.PubMedGoogle Scholar
  15. 15.
    Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–95.PubMedGoogle Scholar
  16. 16.
    Huypens P, Moens K, Heimberg H, Ling Z, Pipeleers D, Van de Casteele M. Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sci. 2005;77:1273–82.PubMedGoogle Scholar
  17. 17.
    Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia–reperfusion injury through. Nat Med. 2005;11:1096–103.PubMedGoogle Scholar
  18. 18.
    Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021–6.PubMedGoogle Scholar
  19. 19.
    Rutter GA, Da Silva XG, Leclerc I. Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J. 2003;375:1–16.PubMedGoogle Scholar
  20. 20.
    Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem. 2003;278: 39422–7.PubMedGoogle Scholar
  21. 21.
    Christ-Crain M, Kola B, Lolli F, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J. 2008;22: 1672–83.PubMedGoogle Scholar
  22. 22.
    Kola B, Christ-Crain M, Lolli F, et al. Changes in adenosine 5′-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing’s syndrome. J Clin Endocrinol Metab. 2008;93:4969–73.PubMedGoogle Scholar
  23. 23.
    Viana AY, Sakoda H, Anai M, et al. Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diabetes Res Clin Pract. 2006; 73:135–42.PubMedGoogle Scholar
  24. 24.
    Kola B, Hubina E, Tucci SA, et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem. 2005;280: 25196–201.PubMedGoogle Scholar
  25. 25.
    Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74.PubMedGoogle Scholar
  26. 26.
    Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–6.PubMedGoogle Scholar
  27. 27.
    El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275:223–8.PubMedGoogle Scholar
  28. 28.
    Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120:2355–69.PubMedGoogle Scholar
  29. 29.
    Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005;437:1109–11.PubMedGoogle Scholar
  30. 30.
    He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137:635–46.PubMedGoogle Scholar
  31. 31.
    Butler H, Korbonits M. Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol. 2009;161:655–62.PubMedGoogle Scholar
  32. 32.
    Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389–462.PubMedGoogle Scholar
  33. 33.
    Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrinol Rev. 2006;27:73–100.Google Scholar
  34. 34.
    Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004;47 Suppl 1:345–58.PubMedGoogle Scholar
  35. 35.
    Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136:550–7.PubMedGoogle Scholar
  36. 36.
    Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822–5.PubMedGoogle Scholar
  37. 37.
    Wittmann G, Deli L, Kallo I, et al. Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus. J Comp Neurol. 2007;503:270–9.PubMedGoogle Scholar
  38. 38.
    Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18:27–37.PubMedGoogle Scholar
  39. 39.
    Kirkham TC, Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets. 2006;5:272–92.PubMedGoogle Scholar
  40. 40.
    Dodd GT, Mancini G, Lutz B, Luckman SM. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. J Neurosci. 2010;30:7369–76.PubMedGoogle Scholar
  41. 41.
    Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005;8:585–9.PubMedGoogle Scholar
  42. 42.
    Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010;120:2953–66.PubMedGoogle Scholar
  43. 43.
    Ellis J, Pediani JD, Canals M, Milasta S, Milligan G. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem. 2006;281:38812–24.PubMedGoogle Scholar
  44. 44.
    Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol. 2005;67:1697–704.PubMedGoogle Scholar
  45. 45.
    Hojo M, Sudo Y, Ando Y, et al. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci. 2008;108:308–19.PubMedGoogle Scholar
  46. 46.
    Schellekens H, Dinan TG, Cryan JF. Lean mean fat reducing “ghrelin” machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity. Neuropharmacology. 2010;58:2–16.PubMedGoogle Scholar
  47. 47.
    Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol. 2004; 143:520–3.PubMedGoogle Scholar
  48. 48.
    Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85:495–522.PubMedGoogle Scholar
  49. 49.
    Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001;50:2540–7.PubMedGoogle Scholar
  50. 50.
    Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992.PubMedGoogle Scholar
  51. 51.
    Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology. 2003;144:544–51.PubMedGoogle Scholar
  52. 52.
    Egecioglu E, Stenstrom B, Pinnock SB, et al. Hypothalamic gene expression following ghrelin therapy to gastrectomized rodents. Regul Pept. 2008;146:176–82.PubMedGoogle Scholar
  53. 53.
    Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003;37:649–61.PubMedGoogle Scholar
  54. 54.
    Shuto Y, Shibasaki T, Otagiri A, et al. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest. 2002;109: 1429–36.PubMedGoogle Scholar
  55. 55.
    Zigman JM, Nakano Y, Coppari R, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest. 2005;115:3564–72.PubMedGoogle Scholar
  56. 56.
    Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology. 2004;145:2607–12.PubMedGoogle Scholar
  57. 57.
    Luquet S, Perez FA, Hnasko TS, Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science. 2005;310:683–5.PubMedGoogle Scholar
  58. 58.
    Dzamko N, van Denderen BJ, Hevener AL, et al. AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J Biol Chem. 2010;285:115–22.PubMedGoogle Scholar
  59. 59.
    Andersson U, Filipsson K, Abbott CR, et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem. 2004;279:12005–8.PubMedGoogle Scholar
  60. 60.
    Kohno D, Sone H, Minokoshi Y, Yada T. Ghrelin raises [Ca2+]i via AMPK in hypothalamic arcuate nucleus NPY neurons. Biochem Biophys Res Commun. 2008;366:388–92.PubMedGoogle Scholar
  61. 61.
    Kola B, Farkas I, Christ-Crain M, et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One. 2008;3:e1797.PubMedGoogle Scholar
  62. 62.
    Lerner RG, Depatie C, Rutter GA, Screaton RA, Balthasar N. A role for the CREB co-activator CRTC2 in the hypothalamic mechanisms linking glucose sensing with gene regulation. EMBO Rep. 2009;10:1175–81.PubMedGoogle Scholar
  63. 63.
    Mozid AM, Tringali G, Forsling ML, et al. Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin. Horm Metab Res. 2003;35:455–9.PubMedGoogle Scholar
  64. 64.
    Whitnall MH, Gainer H. Major pro-vasopressin-expressing and pro-vasopressin-deficient subpopulations of corticotropin-releasing hormone neurons in normal rats. Differential distributions within the paraventricular nucleus. Neuroendocrinology. 1988;47:176–80.PubMedGoogle Scholar
  65. 65.
    Kohno D, Gao HZ, Muroya S, Kikuyama S, Yada T. Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes. 2003; 52:948–56.PubMedGoogle Scholar
  66. 66.
    Anderson KA, Ribar TJ, Lin F, et al. Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab. 2008;7:377–88.PubMedGoogle Scholar
  67. 67.
    Hu Z, Cha SH, Chohnan S, Lane MD. Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci U S A. 2003;100:12624–9.PubMedGoogle Scholar
  68. 68.
    Pocai A, Lam TK, Obici S, et al. Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J Clin Invest. 2006;116:1081–91.PubMedGoogle Scholar
  69. 69.
    Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med. 2003;9:756–61.PubMedGoogle Scholar
  70. 70.
    Wolfgang MJ, Kurama T, Dai Y, et al. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proc Natl Acad Sci U S A. 2006;103:7282–7.PubMedGoogle Scholar
  71. 71.
    Kola B, Korbonits M. Shedding light on the intricate puzzle of ghrelin’s effects on appetite regulation. J Endocrinol. 2009;202:191–8.PubMedGoogle Scholar
  72. 72.
    Lopez M, Lage R, Saha AK, et al. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 2008;7:389–99.PubMedGoogle Scholar
  73. 73.
    Andrews ZB, Liu ZW, Walllingford N, et al. UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals. Nature. 2008;454:846–51.PubMedGoogle Scholar
  74. 74.
    Lage R, Vazquez MJ, Varela L, et al. Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. FASEB J. 2010;24:2670–9.PubMedGoogle Scholar
  75. 75.
    Sakkou M, Wiedmer P, Anlag K, et al. A role for brain-specific homeobox factor Bsx in the control of hyperphagia and locomotory behavior. Cell Metab. 2007;5:450–63.PubMedGoogle Scholar
  76. 76.
    Nogueiras R, Lopez M, Lage R, et al. Bsx, a novel hypothalamic factor linking feeding with locomotor activity, is regulated by energy availability. Endocrinology. 2008;149:3009–15.PubMedGoogle Scholar
  77. 77.
    Sangiao-Alvarellos S, Varela L, Vazquez MJ, et al. Influence of ghrelin and growth hormone deficiency on AMP-activated protein kinase and hypothalamic lipid metabolism. J Neuroendocrinol. 2010;22:543–56.PubMedGoogle Scholar
  78. 78.
    Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin—a hormone with multiple functions. Front Neuroendocrinol. 2004;25:27–68.PubMedGoogle Scholar
  79. 79.
    Toshinai K, Yamaguchi H, Sun Y, et al. Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology. 2006;147:2306–14.PubMedGoogle Scholar
  80. 80.
    Delhanty PJ, Sun Y, Visser JA, et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS One. 2010;5:e11749.PubMedGoogle Scholar
  81. 81.
    Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun. 2000; 279:909–13.PubMedGoogle Scholar
  82. 82.
    Neary NM, Druce MR, Small CJ, Bloom SR. Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect. Gut. 2006;55:135.PubMedGoogle Scholar
  83. 83.
    Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87:2988.PubMedGoogle Scholar
  84. 84.
    Iglesias MJ, Pineiro R, Blanco M, et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. 2004;62:481–8.PubMedGoogle Scholar
  85. 85.
    Chang L, Ren Y, Liu X, et al. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol. 2004;43:165–70.PubMedGoogle Scholar
  86. 86.
    Chang L, Zhao J, Li GZ, et al. Ghrelin protects myocardium from isoproterenol-induced injury in rats. Acta Pharmacol Sin. 2004;25:1131–7.PubMedGoogle Scholar
  87. 87.
    Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol. 2003;98:401–5.PubMedGoogle Scholar
  88. 88.
    Korbonits M, Grossman AB. Ghrelin: update on a novel hormonal system. Eur J Endocrinol. 2004;151 Suppl 1:S67–70.PubMedGoogle Scholar
  89. 89.
    Schwenke DO, Tokudome T, Kishimoto I, et al. Early ghrelin treatment after myocardial infarction prevents an increase in cardiac sympathetic tone and reduces mortality. Endocrinology. 2008;149:5172–6.PubMedGoogle Scholar
  90. 90.
    Nagaya N, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. Regul Pept. 2003;114:71–7.PubMedGoogle Scholar
  91. 91.
    Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004;110:3674–9.PubMedGoogle Scholar
  92. 92.
    Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001;104:1430–5.PubMedGoogle Scholar
  93. 93.
    Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol. 2001;280:R1483–7.PubMedGoogle Scholar
  94. 94.
    Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol. 2002; 159:1029–37.PubMedGoogle Scholar
  95. 95.
    Jessen N, Koh HJ, Folmes CD, et al. Ablation of LKB1 in the heart leads to energy deprivation and impaired cardiac function. Biochim Biophys Acta. 2010;1802:593–600.PubMedGoogle Scholar
  96. 96.
    Ikeda Y, Sato K, Pimentel DR, et al. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J Biol Chem. 2009;284:35839–49.PubMedGoogle Scholar
  97. 97.
    Kusmic C, L’abbate A, Sambuceti G, et al. Improved myocardial perfusion in chronic diabetic mice by the up-regulation of pLKB1 and AMPK signaling. J Cell Biochem. 2010;109:1033–44.PubMedGoogle Scholar
  98. 98.
    Kewalramani G, Puthanveetil P, Wang F, et al. AMP-activated protein kinase confers protection against TNF-{alpha}-induced cardiac cell death. Cardiovasc Res. 2009;84:42–53.PubMedGoogle Scholar
  99. 99.
    Russell III RR, Li J, Coven DL, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest. 2004;114:495–503.PubMedGoogle Scholar
  100. 100.
    Garcia EA, Korbonits M. Ghrelin and cardiovascular health. Curr Opin Pharmacol. 2006;6: 142–7.PubMedGoogle Scholar
  101. 101.
    Xu JP, Wang HX, Wang W, Zhang LK, Tang CS. Ghrelin improves disturbed myocardial energy metabolism in rats with heart failure induced by isoproterenol. J Pept Sci. 2010;16: 392–402.PubMedGoogle Scholar
  102. 102.
    Russell III RR, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol. 1999; 277:H643–9.PubMedGoogle Scholar
  103. 103.
    Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol. 2000; 10:1247–55.PubMedGoogle Scholar
  104. 104.
    Sambandam N, Lopaschuk GD. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog Lipid Res. 2003;42:238–56.PubMedGoogle Scholar
  105. 105.
    Paiva MA, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, Mocanu MM. Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. Cardiovasc Drugs Ther. 2010;24:25–32.PubMedGoogle Scholar
  106. 106.
    Lopaschuk GD. AMP-activated protein kinase control of energy metabolism in the ischemic heart. Int J Obes (Lond). 2008;32 Suppl 4:S29–35.Google Scholar
  107. 107.
    Papotti M, Ghe C, Cassoni P, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. 2000;85:3803–7.PubMedGoogle Scholar
  108. 108.
    Murata M, Okimura Y, Lida K, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem. 2002;277:5667–74.PubMedGoogle Scholar
  109. 109.
    Rigault C, Le BF, Georges B, Demarquoy J. Ghrelin reduces hepatic mitochondrial fatty acid beta oxidation. J Endocrinol Invest. 2007;30:RC4–8.PubMedGoogle Scholar
  110. 110.
    Sangiao-Alvarellos S, Vazquez MJ, Varela L, et al. Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009;150:4562–74.PubMedGoogle Scholar
  111. 111.
    Barazzoni R, Bosutti A, Stebel M, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab. 2005;288:E228–35.PubMedGoogle Scholar
  112. 112.
    Lochhead PA, Salt IP, Walker KS, Hardie DG, Sutherland C. 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes. 2000;49:896–903.PubMedGoogle Scholar
  113. 113.
    Assifi MM, Suchankova G, Constant S, Prentki M, Saha AK, Ruderman NB. AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Am J Physiol Endocrinol Metab. 2005;289:E794–800.PubMedGoogle Scholar
  114. 114.
    Viollet B, Guigas B, Leclerc J, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf). 2009; 196:81–98.Google Scholar
  115. 115.
    Seo E, Park EJ, Joe Y, et al. Overexpression of AMPKalpha1 ameliorates fatty liver in hyperlipidemic diabetic rats. Korean J Physiol Pharmacol. 2009;13:449–54.PubMedGoogle Scholar
  116. 116.
    Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000; 407:908–13.PubMedGoogle Scholar
  117. 117.
    Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001; 280:132–8.PubMedGoogle Scholar
  118. 118.
    Patel AD, Stanley SA, Murphy KG, et al. Ghrelin stimulates insulin-induced glucose uptake in adipocytes. Regul Pept. 2006;134:17–22.PubMedGoogle Scholar
  119. 119.
    Mano-Otagiri A, Iwasaki-Sekino A, Nemoto T, et al. Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats. Regul Pept. 2010; 160:81–90.PubMedGoogle Scholar
  120. 120.
    Davies JS, Kotokorpi P, Eccles SR, et al. Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. Mol Endocrinol. 2009;23:914–24.PubMedGoogle Scholar
  121. 121.
    Gutierrez JA, Solenberg PJ, Perkins DR, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci U S A. 2008;105:6320–5.PubMedGoogle Scholar
  122. 122.
    Gonzalez CR, Vazquez MJ, Lopez M, Dieguez C. Influence of chronic undernutrition and leptin on GOAT mRNA levels in rat stomach mucosa. J Mol Endocrinol. 2008;41:415–21.PubMedGoogle Scholar
  123. 123.
    Thompson NM, Gill DA, Davies R, et al. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology. 2004;145:234–42.PubMedGoogle Scholar
  124. 124.
    Rodriguez A, Gomez-Ambrosi J, Catalan V, et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond). 2009;33:541–52.Google Scholar
  125. 125.
    Liu J, Lin H, Cheng P, Hu X, Lu H. Effects of ghrelin on the proliferation and differentiation of 3T3-L1 preadipocytes. J Huazhong Univ Sci Technolog Med Sci. 2009;29:227–30.PubMedGoogle Scholar
  126. 126.
    Dzamko NL, Steinberg GR. AMPK-dependent hormonal regulation of whole-body energy metabolism. Acta Physiol (Oxf). 2009;196:115–27.Google Scholar
  127. 127.
    Daval M, Diot-Dupuy F, Bazin R, et al. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem. 2005;280:25250–7.PubMedGoogle Scholar
  128. 128.
    Orci L, Cook WS, Ravazzola M, et al. Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad Sci U S A. 2004;101:2058–63.PubMedGoogle Scholar
  129. 129.
    Martinez-Agustin O, Hernandez-Morante J, Martinez-Plata E, de Sanchez MF, Garaulet M. Differences in AMPK expression between subcutaneous and visceral adipose tissue in morbid obesity. Regul Pept. 2010;163:31–6.PubMedGoogle Scholar
  130. 130.
    Baran K, Preston E, Wilks D, Cooney GJ, Kraegen EW, Sainsbury A. Chronic central melanocortin-4 receptor antagonism and central neuropeptide-Y infusion in rats produce increased adiposity by divergent pathways. Diabetes. 2002;51:152–8.PubMedGoogle Scholar
  131. 131.
    Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest. 2006;116:1983–93.PubMedGoogle Scholar
  132. 132.
    Andrews ZB, Erion DM, Beiler R, Choi CS, Shulman GI, Horvath TL. Uncoupling protein-2 decreases the lipogenic actions of ghrelin. Endocrinology. 2010;151:2078–86.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Centre for EndocrinologyWilliam Harvey Research Institute, Barts and The London, Queen Mary’s School of Medicine and Dentisty, Charterhouse SquareLondonUK

Personalised recommendations